Javid Fazili

Contact Information:
Javid Fazili



 

Fazili, Javid (HSC)
Faculty

Department of:

College Of Medicine/Medicine - Gastroenterology -Associate Professor of Medicine

Center of:

Education:

University of Kashmir India, Government Medical College   MBBS   1985
University (Institute of Medical Sciences, Soura, Srinagar, Kashmir, India   M.D.   1994
State University of New York Stony Brook, Nassau County Medical Center   Residency-Internal Medicine   1997
Albert Einstein Medical Center   Fellowship-Gastroenterology   2000
Thomas Jefferson University Hospital   Fellowship-Hepatology   2001

Professional Interest/Expertise/Specializations:
Dr. Fazili has a special interest in hepatology and liver transplantation. His research interests include liver diseases like Hepatitis B, Hepatitis C, and Hepatocellular cancer. He is currently investigating the role of statins in the treatment of hepatitis B infection, tumor markers for hepatocellular carcinoma and markers of cirrhosis in the serum and tissue of patients with liver disease.

Websites:

Department of Internal Medicine-Section of Digestive Diseases and Nutrition
Department of Internal Medicine-Faculty Listing
Veterans Affairs Medical Center-Physician Listing

Research Projects:

Selected Publications:

Review: Mystery of hepatitis e virus: recent advances in its diagnosis and management
2015    Ahmed A, Ali IA, Ghazal H, Fazili J, Nusrat S
Int J Hepatol. 2015;2015:872431 Epub 2015 Jan 19. PMID: 25692043
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4322671/pdf/IJH2015-872431.pdf
Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
2015    Sureban SM, Madhoun MF, May R, Qu D, Ali N, Fazili J, Weygant N, Chandrakesan P, Ding K, Lightfoot SA, Houchen CW
Oncotarget. 2015 Nov 10;6(35):37200-15. doi: 10.18632/oncotarget.5808 PMID: 26468984
http://www.impactjournals.com/oncotarget/index.php?journal=oncotarget&page=article&op=view&path[]=5808&pubmed-linkout=1
Cirrhosis and its complications: evidence based treatment
2014    Nusrat S, Khan MS, Fazili J, Madhoun MF
World J Gastroenterol. 2014 May 14;20(18):5442-60. PMID: 24833875
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017060/pdf/WJG-20-5442.pdf
A randomized controlled trial adding fluvastatin to peginterferon and ribavirin for naïve genotype 1 hepatitis C patients
2013    Bader T, Hughes LD, Fazili J, Frost B, Dunnam M, Gonterman A, Madhoun M, Aston CE
Viral Hepat. 2013 Sep;20(9):622-7. PMID: 23910646
http://onlinelibrary.wiley.com/doi/10.1111/jvh.12085/epdf